Observational Study of the LambdaGuide System for Measurement of Observable Genitourinary Anatomy During Cystoscopic Procedures in Men
This prospective clinical study will evaluate the feasibility, performance, and safety of the LambdaGuide System for obtaining point-to-point measurements of observable genitourinary anatomy during cystoscopic procedures in adult men. The system is intended to provide measurements of anatomical structures visible during cystoscopy without influencing clinical diagnosis or treatment decisions.
The study will assess successful calibration, spatial capture, measurement point selection, and completion of point-to-point measurements. Device usability, procedural workflow effects, and adverse events will also be evaluated. Optional comparisons with known-dimension references may be performed for descriptive purposes.
LambdaGuide measurements will not be used to guide or modify clinical care.
Studienübersicht
Status
Status
Bedingungen
Bedingungen
Detaillierte Beschreibung
This is a prospective, observational clinical study designed to evaluate the feasibility, functional performance, usability, and safety of the LambdaGuide System during cystoscopic procedures in adult male participants aged 22 years and older.
The LambdaGuide System is an investigational optical measurement system that integrates with a compatible cystoscope. It uses an optical camera module, calibration process, spatial capture, and software-based point selection to obtain point-to-point measurements of anatomical structures visible within the urinary tract.
Participants may include men undergoing non-emergency cystoscopic procedures and, where specifically authorized under the approved research protocol, healthy adult male volunteers. Study participation involves use of the LambdaGuide System during cystoscopic visualization. For patients undergoing clinically indicated cystoscopy, the investigational measurements are performed alongside standard clinical care. LambdaGuide measurements will not be used to make diagnostic or therapeutic decisions, select treatment, or modify standard clinical care.
During the procedure, qualified clinicians will set up the LambdaGuide System, perform calibration using an approved calibration target, and attempt measurements of observable urinary anatomy. Potential measurement targets include anatomical openings or narrowing, urethral strictures, distances between anatomical landmarks, urinary tract lesions, stones, foreign bodies, and implant-related structures.
For each measurement attempt, the study will document the ability to obtain spatial information, select two valid measurement points, and display a point-to-point measurement. The primary performance endpoint is procedure-level clinical measurement feasibility, defined as obtaining at least one successful point-to-point measurement during an evaluable procedure.
Additional assessments include calibration success, camera deployment and image display, spatial capture success, measurement completion, calibration and measurement time, procedural interference, and clinician-reported usability. Optional observational comparisons with known-dimension references may be performed. These comparisons are descriptive and are not intended to establish measurement accuracy.
Safety will be evaluated through documentation of adverse events, including their severity, seriousness, and relationship to the investigational device or study procedures. Device deficiencies and malfunctions will also be recorded. Participants will undergo post-procedure safety assessment and follow-up approximately 30 days after the procedure, within a permitted window of ±5 days.
The study is intended to characterize the LambdaGuide System's ability to obtain measurements of visible genitourinary anatomy in a clinical environment and to collect performance, usability, and safety data to support further device evaluation.
Studientyp
Studientyp
Einschreibung (Geschätzt)
Einschreibung
Kontakte und Standorte
Studienkontakt
Studienkontakt
- Name: Sarah Lapp
- Telefonnummer: 678-231-0685
- E-Mail: sarah@lambdasurgical.com
Studienorte
-
-
Massachusetts
-
Boston, Massachusetts, Vereinigte Staaten, 02111
- Rekrutierung
- PINE (Prostate Institution of New England)
-
Kontakt:
- Alethia Chan
- Telefonnummer: 857-800-2305
- E-Mail: chanalethia@gmail.com
-
Hauptermittler:
- Louis Liou, MD, PhD
-
-
Teilnahmekriterien
Zulassungskriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Probenahmeverfahren
Studienpopulation
No additional description beyond Eligibility Criteria. Subjects should be able to travel to a study site.
Beschreibung
Inclusion Criteria:
- Adult male subject (22 years of age or older).
- Subject who undergoes a non-emergency cystoscopic procedure, or a healthy volunteer.
- Able and willing to provide informed consent before study participation.
- Procedure is expected to provide visualization of observable urinary anatomy suitable for an attempted measurement.
- Investigator determines that study participation is appropriate and will not interfere with standard clinical care.
- Investigator determines, based on medical history and physical examination, that the subject is medically appropriate to undergo the study procedures.
Exclusion Criteria:
- Participation is expected to interfere with or materially delay standard clinical care.
- Known clinical condition or procedural circumstance that, in the investigator's judgment, makes study participation inappropriate.
- Inability to provide informed consent.
- Inability to use the required compatible cystoscope or approved study configuration.
- Known allergy or contraindication to the local anesthetic planned for the cystoscopic procedure.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Beobachtungsmodelle: CASE_ONLY
- Zeitperspektiven: PROSPECTIVE
Was misst die Studie?
Primäre Ergebnismessungen
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Clinical measurement feasibility
Zeitfenster: Procedure duration
|
Clinical measurement feasibility, assessed as a procedure-level pass/fail outcome. An evaluable procedure passes if at least one successful point-to-point measurement is obtained. |
Procedure duration
|
|
Primary safety endpoint
Zeitfenster: From procedure date to 30 days after (+/-5 days)
|
Incidence, severity, seriousness, and relatedness of device-related, procedure-related, and other adverse events. |
From procedure date to 30 days after (+/-5 days)
|
Sekundäre Ergebnismessungen
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Maßnahmenbeschreibung |
Zeitfenster |
|---|---|---|
|
Calibration success
Zeitfenster: During Procedure
|
Calibration success |
During Procedure
|
|
Camera deployment and expected image display
Zeitfenster: During Procedure
|
Camera deployment and expected image display |
During Procedure
|
|
Spatial capture success
Zeitfenster: During Procedure
|
Spatial capture success |
During Procedure
|
|
Valid point-selection success
Zeitfenster: During Procedure
|
Valid point-selection success |
During Procedure
|
|
Successful measurement completion
Zeitfenster: During Procedure
|
Successful measurement completion |
During Procedure
|
|
Calibration and measurement time
Zeitfenster: During Procedure
|
Calibration and measurement time (descriptive only) |
During Procedure
|
|
Procedure interference
Zeitfenster: During Procedure
|
Procedure interference |
During Procedure
|
|
User acceptance
Zeitfenster: During Procedure
|
User acceptance - based on Investigator Questionnaire |
During Procedure
|
|
Observational comparative measurements (
Zeitfenster: During Procedure
|
Observational comparative measurements (descriptive only) |
During Procedure
|
Mitarbeiter und Ermittler
Sponsor
Sponsor
Ermittler
Ermittler
- Hauptermittler: Louis Liou, MD, PhD, PINE - Prostate Institution of New England
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn (Geschätzt)
Studienbeginn
Primärer Abschluss (Geschätzt)
Primärer Abschluss
Studienabschluss (Geschätzt)
Studienabschluss
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Tatsächlich)
Zuerst gepostet
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Tatsächlich)
Letztes Update gepostet
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
Andere Studien-ID-Nummern
Andere Studien-ID-Nummern
- LG-GU-001
Plan für individuelle Teilnehmerdaten (IPD)
Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?
Arzneimittel- und Geräteinformationen, Studienunterlagen
Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .